Robert S Weinstein

List of Publications by Year
in descending order

96 papers	17,346 citations	23567 58 h-index	45317 90 g-index
99 all docs	99 docs citations	99 times ranked	12088 citing authors

#	Article	IF	Citations
1	Glucocorticoid-induced osteoporosis and Cushingâ€™s syndrome. , 2021, , 1103-1138.		0
2	Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron. Bone, 2020, 131, 115137.	2.9	3
3	Oxidation-specific epitopes restrain bone formation. Nature Communications, 2018, 9, 2193.	12.8	41
4	The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology, 2017, 158, 3817-3831.	2.8	70
5	Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight, 2017, 2, .	5.0	132
6	Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E762-E773.	3.5	28
7	The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERÎ± Signaling in Osteoblasts and Osteoclasts. Journal of Bone and Mineral Research, 2015, 30, 1138-1149.	2.8	69
8	Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone, 2015, 75, 18-26.	2.9	46
9	FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nature Communications, 2014, 5, 3773.	12.8	202
10	Dysapoptosis of Osteoblasts and Osteocytes Increases Cancellous Bone Formation But Exaggerates Cortical Porosity With Age. Journal of Bone and Mineral Research, 2014, 29, 103-117.	2.8	65
11	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2014, 29, 1-23.	2.8	1,424
12	Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone, 2014, 66, 146-154.	2.9	111
13	Glucocorticoid-Induced Osteoporosis. , 2013, , 1191-1223.		5
14	Osteocyte apoptosis. Bone, 2013, 54, 264-271.	2.9	163
15	Non-Nuclearâ€“Initiated Actions of the Estrogen Receptor Protect Cortical Bone Mass. Molecular Endocrinology, 2013, 27, 649-656.	3.7	50
16	Suppression of Autophagy in Osteocytes Mimics Skeletal Aging. Journal of Biological Chemistry, 2013, 288, 17432-17440.	3.4	165
17	FOXOs attenuate bone formation by suppressing Wnt signaling. Journal of Clinical Investigation, 2013, 123, 3409-3419.	8.2	190
18	Estrogen receptor-Î± signaling in osteoblast progenitors stimulates cortical bone accrual. Journal of Clinical Investigation, 2013, 123, 394-404.	8.2	194

#	Article	IF	Citations
19	The RANKL Distal Control Region Is Required for the Increase in RANKL Expression, But Not the Bone Loss, Associated with Hyperparathyroidism or Lactation in Adult Mice. Molecular Endocrinology, 2012, 26, 341-348.	3.7	27
20	Glucocorticoid-Induced Osteoporosis and Osteonecrosis. Endocrinology and Metabolism Clinics of North America, 2012, 41, 595-611.	3.2	299
21	Glucocorticoid-induced osteonecrosis. Endocrine, 2012, 41, 183-190.	2.3	307
22	Matrix-embedded cells control osteoclast formation. Nature Medicine, 2011, 17, 1235-1241.	30.7	1,115
23	Glucocorticoid-Induced Bone Disease. New England Journal of Medicine, 2011, 365, 62-70.	27.0	575
24	Glucocorticoids and Tumor Necrosis Factor Î± Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts. Journal of Biological Chemistry, 2011, 286, 44326-44335.	3.4	228
25	Osteoprotegerin Prevents Glucocorticoid-Induced Osteocyte Apoptosis in Mice. Endocrinology, 2011, 152, 3323-3331.	2.8	38
26	Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERÎ±. Journal of Bone and Mineral Research, 2010, 25, 769-781.	2.8	99
27	True Strength. Journal of Bone and Mineral Research, 2010, 15, 621-625.	2.8	102
28	Chromosomal Mapping of Osteopenia-Associated Quantitative Trait Loci Using Closely Related Mouse Strains. Journal of Bone and Mineral Research, 2010, 15, 626-633.	2.8	91
29	Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. Journal of Bone and Mineral Research, 2010, 25, 2427-2437.	2.8	64
30	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. Journal of Bone and Mineral Research, 2010, 25, 2267-2294.	2.8	994
31	Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell, 2010, 9, 147-161.	6.7	246
32	Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell, 2010, 9, 851-867.	6.7	108
33	Intermittent Parathyroid Hormone Administration Counteracts the Adverse Effects of Glucocorticoids on Osteoblast and Osteocyte Viability, Bone Formation, and Strength in Mice. Endocrinology, 2010, 151, 2641-2649.	2.8	111
34	The Estrogen Receptor-Î± in Osteoclasts Mediates the Protective Effects of Estrogens on Cancellous But Not Cortical Bone. Molecular Endocrinology, 2010, 24, 323-334.	3.7	233
35	Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone, 2010, 46, 564-570.	2.9	114
36	FoxO-Mediated Defense against Oxidative Stress in Osteoblasts Is Indispensable for Skeletal Homeostasis in Mice. Cell Metabolism, 2010, 11, 136-146.	16.2	249

#	Article	IF	Citations
37	Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nature Reviews Rheumatology, 2009, 5, 341-346.	8.0	28
38	Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone, 2009, 44, 275-286.	2.9	116
39	Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy. New England Journal of Medicine, 2009, 360, 53-62.	27.0	332
40	Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In Vivo. Journal of Bone and Mineral Research, 2008, 23, 1712-1721.	2.8	183
41	Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-Î°B Ligand Gene Reduces Bone Remodeling and Increases Bone Mass. Endocrinology, 2008, 149, 146-153.	2.8	87
42	Apoptosis of Bone Cells. , 2008, , 237-261.		10
43	Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes. PLoS ONE, 2008, 3, e2942.	2.5	331
44	Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 86-87.	2.8	20
45	A novel locus on the X chromosome regulates post-maturity bone density changes in mice. Bone, 2007, 40, 758-766.	2.9	13
46	Skeletal Involution by Age-associated Oxidative Stress and Its Acceleration by Loss of Sex Steroids. Journal of Biological Chemistry, 2007, 282, 27285-27297.	3.4	582
47	Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards. Journal of Bone and Mineral Research, 2007, 22, 1492-1501.	2.8	182
48	Osteocyte Apoptosis Is Induced by Weightlessness in Mice and Precedes Osteoclast Recruitment and Bone Loss. Journal of Bone and Mineral Research, 2006, 21, 605-615.	2.8	414
49	Response to Windahl et al.. Journal of Clinical Investigation, 2006, 116, 2834-2834.	8.2	8
50	Apoptosis in glucocorticoid-induced bone disease. Current Opinion in Internal Medicine, 2005, 4, 337-341.	1.5	1
51	IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E784-E793.	3.5	63
52	11Î²-HSD: Guardian or gate crasher?. BoneKEy Osteovision, 2005, 2, 6-13.	0.6	3
53	Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength. Endocrinology, 2004, 145, 1835-1841.	2.8	685
54	The Skeletal Effects of Glucocorticoid Excess Override Those of Orchidectomy in Mice. Endocrinology, 2004, 145, 1980-1987.	2.8	70

#	Article	IF	Citations
55	Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis International, 2003, 14, 814-822.	3.1	69
56	Human Bone Biopsy. , 2003, , 119-128.		0
57	Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts. Journal of Biological Chemistry, 2003, 278, 50259-50272.	3.4	337
58	Apoptosis in Bone Cells. , 2002, , 151-X.		8
59	Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. Journal of Clinical Investigation, 2002, 109, 1041-1048.	8.2	269
60	Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. Journal of Clinical Investigation, 2002, 109, 1041-1048.	8.2	174
61	The Loss of Smad3 Results in a Lower Rate of Bone Formation and Osteopenia Through Dysregulation of Osteoblast Differentiation and Apoptosis. Journal of Bone and Mineral Research, 2001, 16, 1754-1764.	2.8	153
62	Glucocorticoid Excess During Adolescence Leads to a Major Persistent Deficit in Bone Mass and an Increase in Central Body Fat. Journal of Bone and Mineral Research, 2001, 16, 1879-1885.	2.8	53
63	Glucocorticoid-induced osteoporosis. , 2001, 2, 65-73.		172
64	Apoptosis of Osteocytes in Glucocorticoid-Induced Osteonecrosis of the Hip¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2907-2912.	3.6	310
65	Apoptosis and osteoporosis. American Journal of Medicine, 2000, 108, 153-164.	1.5	242
66	Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation, 1999, 104, 439-446.	8.2	920
67	Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. Journal of Clinical Investigation, 1999, 104, 1363-1374.	8.2	763
68	Alkaline Phosphatase Knock-Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia. Journal of Bone and Mineral Research, 1999, 14, 2015-2026.	2.8	343
69	New Developments in the Pathogenesis and Treatment of Steroid-Inducedâ€‰Osteoporosis. Journal of Bone and Mineral Research, 1999, 14, 1061-1066.	2.8	343
70	Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines. Journal of Bone and Mineral Research, 1998, 13, 793-802.	2.8	499
71	Sonographic findings in Bartholin's gland hamartoma. Journal of Clinical Ultrasound, 1998, 26, 465-469.	0.8	4
72	Parathyroid hormone and corticosteroid-induced osteoporosis. Lancet, The, 1998, 352, 1940.	13.7	5

#	Article	IF	Citations
73	The Effects of Androgen Deficiency on Murine Bone Remodeling and Bone Mineral Density Are Mediated via Cells of the Osteoblastic Lineage*. Endocrinology, 1997, 138, 4013-4021.	2.8	112
74	Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 265-274.	3.6	165
75	Advances in the Treatment of Paget's Bone Disease. Hospital Practice (1995), 1997, 32, 63-77.	1.0	3
76	Letter to the Editor Further Study of the Therapy for Fibrous Dysplasia Is Necessary Reply Wait for Study or Treat? Treat. Journal of Bone and Mineral Research, 1997, 12, 2129-2130.	2.8	0
77	Quantification of Vitamin D Receptor mRNA by Competitive Polymerase Chain Reaction in PBMC: Lack of Correspondence with Common Allelic Variants. Journal of Bone and Mineral Research, 1997, 12, 726-733.	2.8	85
78	Long-Term Aminobisphosphonate Treatment of Fibrous Dysplasia: Spectacular Increase in Bone Density. Journal of Bone and Mineral Research, 1997, 12, 1314-1315.	2.8	78
79	The Effects of Androgen Deficiency on Murine Bone Remodeling and Bone Mineral Density Are Mediated via Cells of the Osteoblastic Lineage. Endocrinology, 1997, 138, 4013-4021.	2.8	28
80	Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. American Journal of Medicine, 1996, 101, 341-348.	1.5	164
81	Fractal geometry and vertebral compression fractures. Journal of Bone and Mineral Research, 1994, 9, 1797-1802.	2.8	83
82	Application of fractal geometry techniques to the study of trabecular bone. Medical Physics, 1993, 20, 1611-1619.	3.0	118
83	Hypercalcemia in Acute Myeloblastic Leukemia is Caused by Osteoclast Activation. American Journal of the Medical Sciences, 1993, 306, 169-173.	1.1	8
84	Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis. Calcified Tissue International, 1990, 46, 361-366.	3.1	26
85	Differences in Mineral Metabolism among Nonhuman Primates Receiving Diets with Only Vitamin D₃or Only Vitamin D₂*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 1282-1290.	3.6	57
86	Diminished Rates of Bone Formation in Normal Black Adults. New England Journal of Medicine, 1988, 319, 1698-1701.	27.0	184
87	Decreased Serum Ionized Calcium and Normal Vitamin D Metabolite Levels with Anticonvulsant Drug Treatment*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 1003-1009.	3.6	175
88	Hypophosphatasia. Medicine (United States), 1984, 63, 12-24.	1.0	115
89	The Histological Heterogeneity of Osteopenia in the Middle-Aged and Elderly Patient. , 1983, , 211-225.		3
90	Qualitative bone defect in uremic osteosclerosis. Metabolism: Clinical and Experimental, 1982, 31, 805-811.	3.4	9

#	Article	IF	Citations
91	Decreased mineralization in hemodialysis patients after subtotal parathyroidectomy. Calcified Tissue International, 1982, 34, 16-20.	3.1	53
92	Focal mineralization defect during disodium etidronate treatment of calcinosis. Calcified Tissue International, 1982, 34, 224-228.	3.1	9
93	Pseudofractures in the absence of osteomalacia. Skeletal Radiology, 1982, 8, 17-19.	2.0	21
94	Ancient bone disease in a Peruvian mummy revealed by quantitative skeletal histomorphometry. American Journal of Physical Anthropology, 1981, 54, 321-326.	2.1	25
95	Heterogeneity of Adult Hypophosphatasia Report of Severe and Mild Cases. Archives of Internal Medicine, 1981, 141, 727.	3.8	51
96	Parathyroid Hormone and 25-Hydroxycholecalciferol Levels in Hypercalcemia of Acute Renal Failure. Archives of Internal Medicine, 1980, 140, 410.	3.8	12